Tag:
Prexige
Latest Headlines
Latest Headlines
Can Novartis salvage a blockbuster hopeful from the scrap heap?
Can a Cox-2 inhibitor pulled from the market four years ago make a comeback? Novartis evidently intends to find out, according to a report from Bloomberg. Citing Novartis's annual report, the
Novartis explores genetic test for side effects
Two years ago the FDA rejected Novartis' Cox-2 inhibitor Prexige on concerns that the drug would cause liver damage in some patients. The osteoarthritis pain drug was once predicted to have yearly
SPOTLIGHT: Prexige gets the boot in UK, Germany
Drug regulators in the UK, Germany, and Austria have suspended Novartis' license to sell Prexige, an arthritis drug linked to possible liver damage.
Wyeth CEO: FDA creating monopoly meds
U.S. drug regulators aren't playing fair, says outgoing Wyeth CEO Bob Essner. New meds that should be allowed on the market--because they're safe and effective--are
Novartis gains Aclasta, loses Prexige
From the good news, bad news file: Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. Reclast
ALSO NOTED: FDA to speed up generic approval; Genfit starts Phase II trials; and much more...
Could the steady trickle of generics approvals out of the FDA suddenly become a rapid stream? The agency is touting an initiative, called Generic Initiative for Value and Efficiency (GIVE), to speed
Diabetes drugs linked to fracture risk
One more strike against diabetes drugs. Australia's regulators are warning that the class of drugs including Avandia and Actos may boost the risk of bone fractures in older women. A four-year study
FDA rejects embattled Novartis drug
Is expected bad news better than unexpected bad? Ask Novartis. Today the company announced the FDA's rejection of the Cox-2 painkiller Prexige--a thumbs-down that
ALSO NOTED: Genzyme has made best offer for Bioenvision; Pfizer wants investigators to pursue ex-employee; GSK licenses IP; and
> Genzyme says its current bid for all the shares of Bioenvision it doesn't already own is its best and final offer.
SPOTLIGHT: Vasella doubtful of Prexige approval
The FDA probably won't approve the Novartis painkiller Prexige now that it's faced regulatory action in
